Watchlist Price Alert

Niagen Bioscience Inc (NAGE)

NASDAQ: NAGE · Real-Time Price · USD

8.94

-0.30 (-3.25%)

At close: May 09, 2025, 3:59 PM

8.95

0.11%

After-hours: May 09, 2025, 04:55 PM EDT

-3.25% (1D)

Bid	8.7
Market Cap	695.09M
Revenue (ttm)	99.6M
Net Income (ttm)	8.55M
EPS (ttm)	0.11
PE Ratio (ttm)	81.27
Forward PE	42.23
Analyst	Buy

Ask	8.96
Volume	1,185,686
Avg. Volume (20D)	994,124
Open	9.22
Previous Close	9.24
Day's Range	8.72 - 9.31
52-Week Range	2.31 - 9.31
Beta	1.95

About NAGE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NAGE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NAGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Niagen Bioscience Inc has released their quartely earnings on May 7, 2025:

Revenue of $30.48M exceeds estimates by $3.41M, with 37.59% YoY growth.

EPS of 0.06 exceeds estimates by 0.04, with 700.00% YoY growth.

Why Price Moved

1 day ago New

+9.35%

Niagen Bioscience shares are trading higher after ... Unlock content with Pro Subscription

News

2 days ago · zacks.com

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.01 per share a year ago.

2 days ago · businesswire.com

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Opera...

4 days ago · businesswire.com

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

1 week ago · businesswire.com

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the scie...

1 month ago · businesswire.com

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science